These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

689 related articles for article (PubMed ID: 19962669)

  • 1. Tissue-penetrating delivery of compounds and nanoparticles into tumors.
    Sugahara KN; Teesalu T; Karmali PP; Kotamraju VR; Agemy L; Girard OM; Hanahan D; Mattrey RF; Ruoslahti E
    Cancer Cell; 2009 Dec; 16(6):510-20. PubMed ID: 19962669
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activatable iRGD-based peptide monolith: Targeting, internalization, and fluorescence activation for precise tumor imaging.
    Cho HJ; Lee SJ; Park SJ; Paik CH; Lee SM; Kim S; Lee YS
    J Control Release; 2016 Sep; 237():177-184. PubMed ID: 27349354
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does ligand-receptor mediated competitive effect or penetrating effect of iRGD peptide when co-administration with iRGD-modified SSL?
    Zhang WQ; Yu KF; Zhong T; Luo LM; Du R; Ren W; Huang D; Song P; Li D; Zhao Y; Wang C; Zhang X
    J Drug Target; 2015 Dec; 23(10):897-909. PubMed ID: 26087869
    [TBL] [Abstract][Full Text] [Related]  

  • 4. iRGD: A Promising Peptide for Cancer Imaging and a Potential Therapeutic Agent for Various Cancers.
    Zuo H
    J Oncol; 2019; 2019():9367845. PubMed ID: 31346334
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor penetrability and anti-angiogenesis using iRGD-mediated delivery of doxorubicin-polymer conjugates.
    Wang K; Zhang X; Liu Y; Liu C; Jiang B; Jiang Y
    Biomaterials; 2014 Oct; 35(30):8735-47. PubMed ID: 25023394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. iRGD peptide conjugation potentiates intraperitoneal tumor delivery of paclitaxel with polymersomes.
    Simón-Gracia L; Hunt H; Scodeller P; Gaitzsch J; Kotamraju VR; Sugahara KN; Tammik O; Ruoslahti E; Battaglia G; Teesalu T
    Biomaterials; 2016 Oct; 104():247-57. PubMed ID: 27472162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor-penetrating peptides.
    Teesalu T; Sugahara KN; Ruoslahti E
    Front Oncol; 2013; 3():216. PubMed ID: 23986882
    [TBL] [Abstract][Full Text] [Related]  

  • 8. De novo design of a tumor-penetrating peptide.
    Alberici L; Roth L; Sugahara KN; Agemy L; Kotamraju VR; Teesalu T; Bordignon C; Traversari C; Rizzardi GP; Ruoslahti E
    Cancer Res; 2013 Jan; 73(2):804-12. PubMed ID: 23151901
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor-penetrating iRGD peptide inhibits metastasis.
    Sugahara KN; Braun GB; de Mendoza TH; Kotamraju VR; French RP; Lowy AM; Teesalu T; Ruoslahti E
    Mol Cancer Ther; 2015 Jan; 14(1):120-8. PubMed ID: 25392370
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Co-Administration Of iRGD Enhances Tumor-Targeted Delivery And Anti-Tumor Effects Of Paclitaxel-Loaded PLGA Nanoparticles For Colorectal Cancer Treatment.
    Zhong Y; Su T; Shi Q; Feng Y; Tao Z; Huang Q; Li L; Hu L; Li S; Tan H; Liu S; Yang H
    Int J Nanomedicine; 2019; 14():8543-8560. PubMed ID: 31802868
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Co-administration of kla-TAT peptide and iRGD to enhance the permeability on A549 3D multiple sphere cells and accumulation on xenograft mice.
    Hu C; Chen X; Huang Y; Chen Y
    Chem Biol Drug Des; 2018 Aug; 92(2):1567-1575. PubMed ID: 29722179
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer therapy with iRGD as a tumor-penetrating peptide.
    Thirumalai A; Girigoswami K; Pallavi P; Harini K; Gowtham P; Girigoswami A
    Bull Cancer; 2023 Dec; 110(12):1288-1300. PubMed ID: 37813754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A tumor-penetrating peptide enhances circulation-independent targeting of peritoneal carcinomatosis.
    Sugahara KN; Scodeller P; Braun GB; de Mendoza TH; Yamazaki CM; Kluger MD; Kitayama J; Alvarez E; Howell SB; Teesalu T; Ruoslahti E; Lowy AM
    J Control Release; 2015 Aug; 212():59-69. PubMed ID: 26071630
    [TBL] [Abstract][Full Text] [Related]  

  • 14. iRGD-targeted delivery of a pro-apoptotic peptide activated by cathepsin B inhibits tumor growth and metastasis in mice.
    Qifan W; Fen N; Ying X; Xinwei F; Jun D; Ge Z
    Tumour Biol; 2016 Aug; 37(8):10643-52. PubMed ID: 26867766
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted Modification of the Cationic Anticancer Peptide HPRP-A1 with iRGD To Improve Specificity, Penetration, and Tumor-Tissue Accumulation.
    Hu C; Huang Y; Chen Y
    Mol Pharm; 2019 Feb; 16(2):561-572. PubMed ID: 30592418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. iRGD tumor-penetrating peptide-modified oncolytic adenovirus shows enhanced tumor transduction, intratumoral dissemination and antitumor efficacy.
    Puig-Saus C; Rojas LA; Laborda E; Figueras A; Alba R; Fillat C; Alemany R
    Gene Ther; 2014 Aug; 21(8):767-74. PubMed ID: 24942629
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs.
    Sugahara KN; Teesalu T; Karmali PP; Kotamraju VR; Agemy L; Greenwald DR; Ruoslahti E
    Science; 2010 May; 328(5981):1031-5. PubMed ID: 20378772
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent advances in the tumor-penetrating peptide internalizing RGD for cancer treatment and diagnosis.
    Qian J; Zhou S; Lin P; Lei J; Zheng S; Xu W; Wang Y; Gao Z; Yang J
    Drug Dev Res; 2023 Jun; 84(4):654-670. PubMed ID: 36959702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor penetrating peptides for improved drug delivery.
    Ruoslahti E
    Adv Drug Deliv Rev; 2017 Feb; 110-111():3-12. PubMed ID: 27040947
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor Penetrating Peptide-Functionalized Tenascin-C Antibody for Glioblastoma Targeting.
    Lingasamy P; Laarmann AH; Teesalu T
    Curr Cancer Drug Targets; 2021; 21(1):70-79. PubMed ID: 33001014
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.